A Phase 2 clinical trial to evaluate the safety and efficacy of an
inhaled anti-MRSA antibiotic is enrolling now.
MRSA + CF
The prevalence of MRSA lung infection in cystic fibrosis (CF) patients has risen in the past decade, currently at 27% in the U.S. Recent publications indicate that chronic Continue reading Attention CF Patients With Persistent MRSA Lung Infection
BOULDER, Colo., March 12, 2014 /PRNewswire/ — N30 Pharmaceuticals, Inc. (“N30 Pharma”) announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF). Continue reading N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy
The vast majority of Cystic Fibrosis treatments currently approved by the Food and Drug Administration focus on managing and curtailing symptoms of the disease rather than treating its underlying causes. However, a new pharma report from GBI Research Continue reading New Analysis Indicates Cystic Fibrosis Transmembrane Conductance Regulator Modulators Will Lead To Significant Treatment Improvements
Individuals with cystic fibrosis can earn $50 from home by donating only a small amount of blood to researchers seeking new treatments, diagnostics and cures. Continue reading Sanguine Biosciences is seeking blood donors to help cystic fibrosis researchers.
A new phase II trial is currently recruiting cystic fibrosis (CF) patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection to determine the effectiveness, safety, and pharmacokinetics of a new investigational inhalable powder formulation of vancomycin called Continue reading MRSA trial now recruiting patients
Clinical trials are vital part of advancing treatments for CF patients. Fundraising is the genesis for new treatments because it allows researchers to create new treatments, but clinical trials are the bridge from a breakthrough in the lab to a new medicine actually being available on the open Continue reading Clinical Trials: A Vital Part of Cystic Fibrosis Treatment Advancements
KaloBios Pharmaceuticals Inc. (KBIO) said the U.S. Food and Drug Administration granted orphan-drug designation for its treatment for cystic fibrosis patients with Pseudomonas aeruginosa. Continue reading KaloBios Says Cystic Fibrosis-Related Treatment Gains Orphan-Drug Status
Pharmaceutical discovery and development company Celtaxsys, Inc. today announced it is now enrolling patients for its first trial of CTX-4430 oral treatment for lung disease in Cystic Fibrosis (CF) patients. In this study, the safety and Continue reading Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients
Imagine you can go anywhere for medical care, at any time of the day, and ensure that the people treating you know exactly how to take care of you. Imagine you can also directly help the medical researchers that are trying to help you….and Continue reading Take A Two Question Survey Regarding Medical Records Bank (MRB) Initiative
A new study led by Dr Gergely Lukacs, from the Physiology Department at McGill University, in Canada, reveals new information about the disease known as cystic fibrosis. Cystic fibrosis (CF), also known as mucoviscidosis, is a life threatening disease that severely affects the digestive system and the lungs. Continue reading Novel Therapy Against Cystic Fibrosis Discovered by Researchers